Medication info
Ectorin Met Tablet 15/850 mg (Pioglitazone, Metformin Hydrochloride)

Ectorin Met Tablet 15/850 mg (Pioglitazone, Metformin Hydrochloride)

Prescription medicationTablet
Ingredient · strength
Metformin Hydrochloride›850mg / 1 tabletPioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Nexpharm Korea Co., Ltd.
Appearance
White to grayish-white rectangular film-coated tablet
Packaging
30 tablets/box [(10 tablets/PTP*3)]
Approval status
Active

MFDS item code 201902708 · Approved 2019.04.29 · Insurance code 662504930

Summary

Main use
Improvement of blood glucose control in patients with type 2 diabetes
Who uses it
Adults
Adult dosage
For the treatment of patients with type 2 diabetes, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with metformin or pioglitazone monotherapy: The dose should be based on the dose of metformin or pioglitazone currently being taken. Start with 1 tablet of this medicine daily and gradually adjust the dose after evaluating the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at the doses of pioglitazone and metformin they were previously receiving. No studies have been conducted to examine the safety and efficacy of switching from other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not have their dose increased to the maximum dose of this medicine. After administering this medicine to patients, or when increasing the dose, patients must be carefully monitored for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals, which may reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is needed to evaluate the adequacy of the treatment response. Ideally, the response to treatment should be evaluated using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1C reflects blood glucose levels over the past 2 - 3 months. In clinical use of this medicine, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) to evaluate changes in HbA1C is recommended.

Ingredients

Manufacturer
Nexpharm Korea Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in patients with type 2 diabetes

View approved original text

This medication helps improve blood sugar control in patients with type 2 diabetes by taking pioglitazone and metformin together. It is more effective when used alongside diet and exercise therapy. Therefore, it is used as an adjunctive treatment to aid in blood sugar management.

Dosage and Administration

Adult dosage

For the treatment of patients with type 2 diabetes, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with metformin or pioglitazone monotherapy: The dose should be based on the dose of metformin or pioglitazone currently being taken. Start with 1 tablet of this medicine daily and gradually adjust the dose after evaluating the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at the doses of pioglitazone and metformin they were previously receiving. No studies have been conducted to examine the safety and efficacy of switching from other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not have their dose increased to the maximum dose of this medicine. After administering this medicine to patients, or when increasing the dose, patients must be carefully monitored for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals, which may reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is needed to evaluate the adequacy of the treatment response. Ideally, the response to treatment should be evaluated using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1C reflects blood glucose levels over the past 2 - 3 months. In clinical use of this medicine, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) to evaluate changes in HbA1C is recommended.

Precautions

This medication assists in controlling blood sugar levels. However, there are several important precautions when taking this medication. First, this medication should not be used in patients with impaired kidney function or severe heart failure. If kidney function deteriorates, the medication may accumulate in the body and pose risks. Second, this medication can cause a rare but serious side effect called lactic acidosis. Lactic acidosis occurs when there is excessive buildup of lactic acid in the body, with symptoms including fatigue, muscle pain, shortness of breath, and abdominal pain. If these symptoms appear, it is essential to inform a doctor immediately and discontinue the medication. Third, patients with impaired liver function should not take this medication, and it is important to regularly check liver health. Fourth, excessive alcohol consumption should be avoided while taking this medication. Alcohol may increase the risk of side effects from the medication. Fifth, heart failure patients should be closely monitored as symptoms may worsen with this medication, and medical consultation should be sought immediately if symptoms arise. Sixth, this medication should be administered with caution to patients with a history of bladder cancer, and if bladder-related symptoms (hematuria, urination disorders, etc.) occur, the doctor should be notified immediately. Seventh, pregnant or breastfeeding women should not take this medication, and safety has not been established for children. Eighth, the elderly may have reduced kidney function, so the dosage of this medication should be carefully adjusted and kidney function assessed regularly. Finally, this medication may interact with other medications, so it is necessary to inform healthcare providers of all medications being taken and to monitor treatment effects and side effects through regular blood sugar tests and blood tests.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • fatigue
  • myalgia
  • dyspnea
  • asthenia
  • abdominal pain
  • hypothermia
  • hypotension
  • resistant bradyarrhythmia
Show 33 more
  • congestive heart failure
  • excessive and rapid weight change
  • edema
  • upper respiratory infection
  • diarrhea
  • complex edema
  • headache
  • nausea
  • urinary tract infection
  • sinusitis
  • dizziness
  • lower limb edema
  • weight gain
  • myalgia
  • dental disorders
  • worsening of diabetes
  • pharyngitis
  • anemia
  • decreased vision
  • diabetic macular edema
  • liver failure
  • dyspepsia
  • insomnia
  • dry mouth
  • constipation
  • abdominal distension
  • gastroesophageal reflux disease
  • intraluminal gas distension
  • increased serum creatinine
  • increased serum urea
  • fracture
  • urinary disturbance
  • urgency

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is also recommended to store it at room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

White to grayish-white rectangular film-coated tablet

Package unit

30 tablets/box [(10 tablets/PTP*3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.